- Home
- PRLB vs OCS Comparison
PRLB vs OCS Comparison
Compare PRLB & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLB
- OCS
- Stock Information
- Founded
- PRLB 1999
- OCS 2003
- Country
- PRLB United States
- OCS Switzerland
- Employees
- PRLB N/A
- OCS N/A
- Industry
- PRLB Metal Fabrications
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- PRLB Industrials
- OCS Health Care
- Exchange
- PRLB Nasdaq
- OCS Nasdaq
- Market Cap
- PRLB 957.7M
- OCS 863.5M
- IPO Year
- PRLB 2012
- OCS N/A
- Fundamental
- Price
- PRLB $37.14
- OCS $18.40
- Analyst Decision
- PRLB Buy
- OCS Strong Buy
- Analyst Count
- PRLB 4
- OCS 4
- Target Price
- PRLB $43.67
- OCS $28.75
- AVG Volume (30 Days)
- PRLB 247.5K
- OCS 53.4K
- Earning Date
- PRLB 05-02-2025
- OCS 05-07-2025
- Dividend Yield
- PRLB N/A
- OCS N/A
- EPS Growth
- PRLB 0.37
- OCS N/A
- EPS
- PRLB 0.66
- OCS N/A
- Revenue
- PRLB $500,890,000.00
- OCS $1,027,572.00
- Revenue This Year
- PRLB $3.49
- OCS $8.06
- Revenue Next Year
- PRLB $4.82
- OCS $638.57
- P/E Ratio
- PRLB $56.14
- OCS N/A
- Revenue Growth
- PRLB N/A
- OCS N/A
- 52 Week Low
- PRLB $25.76
- OCS $10.55
- 52 Week High
- PRLB $46.73
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- PRLB 35.10
- OCS 33.84
- Support Level
- PRLB $36.96
- OCS $17.92
- Resistance Level
- PRLB $38.55
- OCS $19.22
- Average True Range (ATR)
- PRLB 1.31
- OCS 0.58
- MACD
- PRLB -0.44
- OCS -0.27
- Stochastic Oscillator
- PRLB 8.73
- OCS 12.18
About PRLB Proto Labs Inc. Common stock
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. The majority of its revenue is derived from the United States of America.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.